AKT PUBLICATION

International Journal of Pharmacognosy and Herbal Drug Technology (IJPHDT)
ISSN: 3049-1630 | Vol. 03, Issue 04, April-2026 | pp. 127-147

ORIGINAL ARTICLE https://www.aktpublication.com

Phytoestrogens for Polycystic Ovary Syndrome (PCOS): Natural Approaches to Hormonal Balance

Jai Shankar Pandey[1*], Prashant Kumar [2], Aditya Kumar Jaiswal[1], Rohit Rajak[1], Shubham Kumar Maurya[1]

[1]Faculty of Nursing and Paramedical, Mahayogi Gorakhnath University Gorakhpur, Gorakhpur, Uttar Pradesh, India

[2]Guru Shree Gorakshnath Chikitsalay Gorakhpur, Uttar Pradesh, India

***Corresponding Author E-mail: pandeyjai01@gmail.com**

Abstract

Phytoestrogens, a diverse group of naturally occurring plant-derived chemicals that resemble estradiol, have garnered considerable interest for their potential effects on insulin sensitivity and glucose metabolism. These chemicals primarily exert their effects via estrogen receptors and numerous signaling pathways, including PI3K/Akt, AMPK, and PPARγ, therefore influencing glucose absorption, lipid metabolism, and inflammatory responses. Experimental and clinical investigations have demonstrated favorable benefits of phytoestrogens, notably isoflavones such as genistein and daidzein, in diminishing insulin resistance, enhancing β-cell functionality, and alleviating characteristics of metabolic syndrome. Nonetheless, interindividual heterogeneity, particularly concerning gut microbiota and equol-producing capability, influences efficacy findings. Although phytoestrogens provide a botanical and practical method for addressing insulin resistance and associated metabolic conditions, such as type 2 diabetes and PCOS, comprehensive safety data and extensive clinical validation are still insufficient. This review rigorously examines the mechanisms of action, preclinical and clinical data, and prospective therapeutic potential of phytoestrogens in enhancing insulin sensitivity.

Keywords: Phytoestrogens, Insulin Sensitivity, Genistein, Type 2 Diabetes, PCOS

Received: Jan. 17, 2026 **Revised: Feb. 16, 2026** **Accepted: March 26, 2026** **Published: April 28, 2026**

DOI: https://doi.org/10.64063/3049-1630.vol3.issue4.000243

https://ijphdt.com

1.Introduction

Insulin resistance (IR) is a critical pathophysiological mechanism in several chronic metabolic disorders, including type 2 diabetes mellitus (T2D), polycystic ovarian syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD), cardiovascular disease (CVD), and obesity. Insulin resistance at the cellular level is characterized by a diminished ability of insulin to facilitate glucose uptake, glycogen synthesis, and lipid regulation, especially in insulin-sensitive tissues such as skeletal muscle, liver, and adipose tissue[1] . The persistent nature of insulin resistance results in compensatory hyperinsulinemia, systemic inflammation, lipid irregularities, and finally beta-cell failure and hyperglycemia. Although pharmacological therapies like metformin, thiazolidinediones, and GLP-1 agonists have demonstrated effectiveness in addressing insulin resistance, there is a growing interest in investigating plant-based dietary approaches that utilize bioactive substances with potential insulin-sensitizing effects [2] . Phytoestrogens have attracted considerable interest among these substances because of their structural resemblance to 17β-estradiol and their capacity to influence estrogen receptors signaling along with many metabolic and inflammatory pathways. Phytoestrogens, mostly located in soy, flaxseed, legumes, and whole grains, include isoflavones, lignans, and coumestans [3] . They have modest estrogenic or anti-estrogenic effects contingent upon the target tissue, receptor subtype, and endogenous hormone concentrations. Recent research indicates that phytoestrogens can influence several facets of insulin action, encompassing insulin receptor signaling, glucose transporter expression, pancreatic beta-cell functionality, lipid metabolism, oxidative stress, and the generation of inflammatory cytokines [4] . This review thoroughly examines the definition, categorization, sources, and mechanistic functions of phytoestrogens in enhancing insulin sensitivity, utilizing insights from molecular biology, pharmacology, epidemiology, and clinical trial data. It also examines their therapeutic potential, comparative advantages over conventional estrogen treatments, and future prospects for their incorporation into dietary strategies aimed at enhancing metabolic health [5] .

1.1 Definition

Phytoestrogens are naturally occurring plant chemicals that physically and functionally resemble endogenous estrogens. They are polyphenolic compounds that can bind to estrogen receptors (ERα and ERβ), either beginning estrogen-like signaling or antagonizing the effects of endogenous estrogens, depending on the tissue contex[6] . Despite their estrogenic potency being many orders of magnitude lower than that of 17β-estradiol, substantial food consumption and cumulative exposure may impart biological activity adequate to influence endocrine and metabolic processes. The structural similarity of phytoestrogens to 17β-estradiol allows them to modulate estrogenic activity in metabolic tissues[7.] (Figure 6.1).

The three primary classifications of phytoestrogens are:

- Isoflavones: These are the most well-researched phytoestrogens, notably prevalent in soybeans and soy-based products. The principal isoflavones, genistein, daidzein, and glycitein, are present in plants as glycoside conjugates and are transformed by intestinal bacteria into accessible aglycones. Daidzein may be converted into equol, a molecule with markedly greater estrogen receptor affinity, but only in persons possessing certain gut microbial assemblages referred to be equol producers [8] .
- Lignans are extensively found in seeds, especially flaxseed, as well as in cereals, fruits, and vegetables. Secoisolariciresinol diglucoside (SDG) and matairesinol are metabolized

by colonic bacteria into enterodiol and enterolactone, bioactive enterolignans with estrogenic properties [9].

- Coumestans: Coumestrol is the most prominent coumestan, occurring in significant proportions in sprouting legumes such as alfalfa and clover. It is less common in the human diet than isoflavones and lignans; however, it has a comparatively strong affinity for ERβ[10].

FIGURE 1: Structural comparison between 17β-estradiol and representative phytoestrogens. Created in ChemDraw by the Author.



TABLE 1: Effects of phytoestrogens on insulin sensitivity and related metabolic parameters.

Phytoestrogen Class	Representative Compounds	Rich Dietary Sources	Reference
Isoflavones	Genistein, Daidzein	Soybeans, tofu, tempeh, soy milk, edamame	11
			12
Lignans	Secoisolariciresinol	Flaxseed, sesame seeds, rye, oat bran, broccoli	13
Coumestans	Coumestrol	Alfalfa sprouts, split peas, pinto beans, clover	14

The phytoestrogen level in foods can fluctuate considerably due to farming practices, processing techniques, storage conditions, and geographic origin. For instance, traditional Japanese and Korean diets may have 20–50 mg/day of isoflavones, but Western diets often contain less than 2 mg/day. Table 1

2. Relationship between Phytoestrogens and Insulin Sensitivity

The relationship between phytoestrogens and insulin sensitivity is complex, including hormonal, metabolic, and inflammatory processes. Insulin resistance, a hallmark of T2DM, is characterized by reduced cellular responsiveness to insulin in peripheral organs such as the liver, muscle, and adipose tissue. Thus, the ability of phytoestrogens to affect insulin signaling is a crucial area of research[15.]

2.1 Phytoestrogens and Type 2 Diabetes Mellitus

A plethora of observational and interventional studies have investigated the impact of dietary phytoestrogens on glycemic control in individuals with type 2 diabetes mellitus. These studies have highlighted the ability of phytoestrogens to:

- Reduce fasting glucose and insulin concentrations
- Enhance HbA1c levels
- Augment insulin receptor sensitivity

Regulate glucose transporter function (particularly GLUT4) [16-17]. Epidemiological statistics indicate a reduced prevalence of T2DM and metabolic syndrome in populations with elevated dietary soy consumption, particularly in East Asian nations. The protective effect is partially ascribed to the regular consumption of isoflavones, which are thought to function through many intracellular signaling pathways to enhance glucose homeostasis [18.]

2.2 Mechanistic Insights: Linking Phytoestrogens to Improved Insulin Sensitivity

Phytoestrogens may improve insulin sensitivity via several biological mechanisms:

Estrogenic Activity: Phytoestrogens can either imitate or counteract natural estrogen actions by binding to estrogen receptors, particularly ERβ. Estrogen regulates insulin sensitivity, and the reduction of estrogen levels during menopause correlates with heightened insulin resistance. Phytoestrogens may work as viable substitutes by maintaining estrogenic signaling in metabolic tissues. Activation of the AMPK Pathway: Isoflavones, including genistein, have shown the capacity to activate AMP-activated protein kinase (AMPK), an essential regulator of cellular energy homeostasis [19] . The activation of AMPK enhances insulin sensitivity by promoting glucose uptake, increasing fatty acid oxidation, and driving mitochondrial biogenesis, particularly in skeletal muscle and liver cells. Regulation of the PI3K/Akt Pathway: The phosphatidylinositol l 3-kinase (PI3K)/Akt signaling pathway is essential for insulin-mediated glucose uptake. Phytoestrogens have demonstrated the ability to boost this mechanism, leading to increased translocation of GLUT4 to the cell membrane and improved glucose utilization [20] . Effects of Anti-Inflammation and Antioxidation: Chronic low-grade inflammation and oxidative stress are critical contributors to the development of insulin resistance. Phytoestrogens exert anti-inflammatory effects by inhibiting NF-κB signaling and reducing pro-inflammatory cytokines, such as TNF-α and IL-6. Their antioxidant qualities reduce oxidative damage to insulin-sensitive tissues, hence enhancing insulin effectiveness [21] . The makeup of gut microbiota influences insulin sensitivity. Phytoestrogens can affect gut microbial diversity and promote the growth of beneficial bacteria such as Bifidobacterium and Lactobacillus, thereby enhancing metabolic health and reducing systemic inflammation.

2.3 Gender and Age Differences

The influence of phytoestrogens on insulin sensitivity may vary depending on sex, age, and hormonal status. In postmenopausal women, phytoestrogens may offer increased benefits owing to estrogen insufficiency. In younger individuals with heightened endogenous estrogen levels, phytoestrogens may act more as modulators than as substitutes. Moreover, genetic polymorphisms affecting phytoestrogen metabolism (e.g., equol-producer status) may alter individual susceptibility to dietary phytoestrogens [22] .

2.4 Dietary Patterns and Synergistic Effects

It is crucial to recognize that phytoestrogens are ingested not in isolation but within intricate dietary frameworks. Diets abundant in whole grains, legumes, fruits, and vegetables may collaborate with phytoestrogens to enhance insulin sensitivity. The Mediterranean and Asian dietary patterns, noted for their elevated phytonutrient and fiber levels, have repeatedly been linked to reducing insulin resistance and enhancing metabolic profiles [23] . These pathways collectively enhance insulin sensitivity, as depicted in Figure 6.2**.** The association between phytoestrogens and insulin sensitivity is substantiated by molecular, epidemiological, and clinical research. Nevertheless, more randomized controlled studies are required to ascertain appropriate dosages, types (e.g., aglycones vs glycosides), and durations of phytoestrogen consumption for enhancing metabolic outcomes across varied populations [24.]

FIGURE 2: Mechanistic Pathways of Phytoestrogens in Improving Insulin Sensitivity



2.5 Mechanisms of Action – Estrogen-Independent Pathways

Although estrogen-dependent processes are pivotal in the impact of phytoestrogens on insulin sensitivity, recent research highlights the importance of estrogen-independent routes. These pathways enable phytoestrogens to provide metabolic effects without attaching to estrogen receptors (ERα and ERβ), so enhancing their therapeutic potential in both males and females with metabolic diseases, including type 2 diabetes (T2D) and PCOS [25] .

2.6 Effects on Pancreatic β-Cell Function and Insulin Secretion

A crucial estrogen-independent function of phytoestrogens is the preservation and enhancement of pancreatic β-cell functioning. These cells are responsible for the production, storage, and secretion of insulin. A multitude of in vitro and in vivo studies demonstrate that phytoestrogens, including genistein, daidzein, and coumestrol, directly boost β-cell proliferation, reduce apoptosis, and augment glucose-stimulated insulin secretion (GSIS) [26] .

Genistein enhances the cyclic AMP/protein kinase A (cAMP/PKA) signaling pathway in β-cells, hence facilitating insulin exocytosis. Phytoestrogens enhance the expression of the transcription factors PDX-1 and MafA, which are essential regulators of β-cell maturation and insulin gene expression. Moreover, they alleviate oxidative stress and mitochondrial dysfunction in β-cells, which are critical contributors to β-cell failure in type 2 diabetes [27] . The insulinotropic effect, independent of estrogen receptor activation, highlights the importance of phytoestrogens in enhancing pancreatic endocrine function, even in individuals with reduced estrogen levels or resistance to estrogen receptors. The overall estrogen-independent influence of phytoestrogen on metabolic function is illustrated in Figure 6.3[28.]

FIGURE 3: Chemical structure of the synthesized 5-FU/ASA hybrid. Created in ChemDraw and BioRender by the Author.



2.7 Modulation of Adiposity and Lipid Metabolism

A notable estrogen-independent mechanism is the influence of phytoestrogens on adipose tissue functionality and lipid metabolism. Adiposity is pivotal in the development of insulin resistance, mostly by the secretion of pro-inflammatory adipokines, including TNF-α and IL-

6, which disrupt insulin signaling [28] . Phytoestrogens attenuate adipogenesis by downregulating PPARγ, a regulator of adipocyte differentiation. They enhance lipolysis and fatty acid β-oxidation via AMPK activation, fostering a leaner body composition. Numerous flavonoids and lignans boost adipokine profiles by increasing adiponectin levels, a crucial hormone that improves insulin sensitivity. Furthermore, these substances have demonstrated the ability to diminish ectopic fat deposition in the liver and skeletal muscle, alleviating insulin resistance induced by lipotoxicity [29-30] .

3. Antioxidant and Anti-inflammatory Actions

Oxidative stress and persistent inflammation are hallmark features of insulin resistance and metabolic syndrome. Phytoestrogens, particularly those sourced from soy and flaxseed, exhibit considerable antioxidant properties due to their polyphenolic structure. They neutralize reactive oxygen species (ROS) and enhance the function of inherent antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase (GPx) [31] . Phytoestrogens attenuate NF-κB signaling, thereby reducing the production of inflammatory cytokines such as IL-1β, TNF-α, and IL-6. These actions preserve the integrity of insulin receptor signaling by obstructing inflammatory serine phosphorylation of IRS-1 (insulin receptor substrate-1) [32] . Regulation of Gastrointestinal Microbiota and Short-Chain Fatty Acids (SCFAs) Recent studies have highlighted the gut microbiota as a crucial mediator in the relationship between phytoestrogens and metabolic health. Phytoestrogens can alter the composition of gut microbiota, facilitating the growth of butyrate-producing taxa such as Roseburia and Faecalibacterium prausnitzii. These bacteria produce short-chain fatty acids (SCFAs), including butyrate and propionate, which improve insulin sensitivity by activating GPR41/43 receptors and increasing the release of glucagon-like peptide-1 (GLP-1). Moreover, the gut-mediated metabolism of phytoestrogens enhances their bioavailability and potency, especially via the production of equol, a powerful isoflavone metabolite[33-34] .

3.1 Epigenetic Regulation of Metabolic Genes

- Phytoestrogens have been shown to exert epigenetic modifications on genes involved in glucose and lipid metabolism. These include changes in:
- DNA methylation, particularly in promoter regions of genes like GLUT4, IRS-1, and adiponectin.
- Histone acetylation which can either suppress or enhance transcriptional activity of metabolic genes.

These epigenetic actions provide a long-lasting regulatory effect that may contribute to sustained improvements in metabolic control, especially when phytoestrogens are consumed early in life or consistently over time [35-36] .

4. Clinical Evidence

4.1 Clinical Trials

Numerous randomized controlled trials (RCTs) and interventional studies have examined the effects of phytoestrogens on insulin resistance and glycemic regulation, especially in groups at elevated risk for metabolic syndrome and type 2 diabetes (T2D). These trials offer essential insights into the therapeutic effectiveness of phytoestrogens and clarify their potential as alternatives or supplements to traditional antidiabetic treatments [37].

4.2.Clarification of Dosage and Safety

The phytoestrogen dosages administered in these clinical trials, varying from 40 mg/day to 600 mg/day, are often more than the average Western food consumption. For instance, the typical isoflavone intake in traditional Asian cuisines (e.g., Japanese or Korean) varies from 20 to 50 mg per day, but it is less than 2 mg per day in Western cultures. Likewise, lignans generated from flaxseed, such as SDG, are ingested in lesser quantities in standard diets compared to the 600 mg/day utilized in certain treatments [38].

Significantly, these dosages have exhibited superior safety profiles in short- and mid-term investigations. Most clinical recommendations regarding isoflavone consumption of up to 100 mg/day and lignan consumption of up to 1 g/day as considered safe for the general population, including postmenopausal women[39] . Minor side effects, including gastrointestinal pain, have been recorded; however, no substantial detrimental effects on liver enzymes, endometrial thickness, or hormonal parameters were noted. The results indicate that supplementation at clinically significant levels is effective and well-tolerated [40].

4.1.1 Soy Isoflavones in Postmenopausal Women with Type 2 Diabetes

The demography most thoroughly examined in phytoestrogen studies comprises postmenopausal women, as the decline in estrogen after menopause results in metabolic disruptions. A 12-week double-blind randomized controlled experiment assessed the effects of soy isoflavone supplementation (delivering 54 mg/day of genistein, daidzein, and glycitein) in postmenopausal women with type 2 diabetes [42] . The results indicated substantial decreases in fasting glucose (−8%), HbA1c (−0.6%), and fasting insulin levels (−10%) relative to the placebo group. Enhancements were observed in lipid profiles, namely LDL cholesterol (−12%) and total cholesterol (−9%) [43].

4.1.2 Genistein Supplementation and Insulin Sensitivity

A distinct randomized controlled study (RCT) with obese postmenopausal women showed that a daily administration of 54 mg of genistein over 6 months improved insulin sensitivity, as measured by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). Participants exhibited heightened adiponectin levels and reduced TNF-α and CRP, signifying anti-inflammatory mechanisms contributing to improved insulin sensitivity [44] .

4.1.3 Daidzein and Gut Microbiota Modulation

An interventional study providing daidzein (40 mg/day for 8 weeks) in overweight individuals showed improvements in glucose tolerance and insulin response during oral glucose tolerance tests (OGTT). The study indicated a significant increase in the population of gut bacteria that promotes equol production. Equol is a more bioactive metabolite of daidzein, demonstrating a greater affinity for estrogen receptors. This suggests that the composition of gut microbiota affects personal reactions to phytoestrogens. [45]

4.1.4 Flaxseed Lignans and Glycemic Control

Flaxseed lignans, namely secoisolariciresinol diglucoside (SDG), have demonstrated promise in regulating insulin dynamics. Research including T2D patients administered 600 mg/day of SDG for 12 weeks demonstrated a reduction in fasting plasma glucose and enhanced insulin sensitivity. The effects were ascribed to antioxidant and anti-inflammatory capabilities, in addition to moderate regulation of estrogen receptors [46] .

4.1.5 Combination Trials and Long-Term Effects

Combination experiments utilizing soy protein supplemented with isoflavones in conjunction with lifestyle treatments have exhibited synergistic benefits. One-year research integrating dietary soy with physical exercise and calorie restriction saw substantial enhancements in body weight, waist circumference, insulin sensitivity, and overall metabolic health [47] .

4.1.6 Safety and Tolerability

In clinical studies, phytoestrogen supplementation has demonstrated good tolerability, with few side effects noted. Frequently noted adverse effects encompass modest gastrointestinal issues, which were temporary. Notably, most long-term trials revealed no significant changes in liver enzymes or endometrial thickness, indicating a positive safety profile [48] .

4.2 Epidemiological Studies

Epidemiological studies offer extensive, population-level insights into the enduring relationships between phytoestrogen consumption and insulin sensitivity. These observational studies augment clinical trial data by examining habitual food habits and their effects on metabolic health outcomes 49.

4.2.1 Dietary Surveys and Insulin Sensitivity

Cross-sectional studies from the National Health and Nutrition Examination Survey (NHANES) and several regional dietary surveys have identified a favorable link between increased phytoestrogen consumption and enhanced indicators of insulin sensitivity. Individuals in the highest quartile of soy isoflavone or lignan consumption consistently exhibited reduced fasting glucose and insulin levels relative to those in the lowest quartile[50].

4.2.2 Prospective Cohort Studies

In prospective cohort studies, including the Shanghai Women's Health Study and the Nurses' Health Study, women with elevated dietary isoflavone consumption exhibited a markedly reduced risk of developing type 2 diabetes throughout follow-up periods of 5 to 10 years. Adjusted hazard ratios indicated a 20–30% reduction in risk, even after accounting for age, BMI, physical activity, and other confounding variables [51] .

4.2.3 Global Patterns and Dietary Sources

Global epidemiological analyses indicate a reduced frequency of metabolic syndrome and insulin resistance among communities adhering to traditional Asian diets abundant in soy, miso, tofu, and tempeh. These dietary patterns are associated with a decreased risk of T2D and a decrease in cardiovascular morbidity, highlighting the systemic advantages of phytoestrogens [52].

4.2.4 Biomarker-Based Studies

Certain studies have employed plasma and urine biomarkers of phytoestrogens (e.g., genistein, daidzein, enterolactone) to quantitatively assess exposure. The levels of these biomarkers exhibit a high correlation with enhanced HOMA-IR scores, reduced CRP levels, and superior lipid profiles, underscoring the advantageous effect of phytoestrogens in metabolic control [53].

4.2.5 Limitations and Confounding Factors

Epidemiological findings indicate a protective function for phytoestrogens; nevertheless, limitations like self-reported food consumption, memory bias, and uncontrolled confounders must be recognized. Moreover, differences in phytoestrogen bioavailability resulting from gut microbiota variety and genetic polymorphisms might affect individual responses[54].

FIGURE 4: Comparative Effects of Phytoestrogens vs. Conventional Therapies on Insulin Sensitivity Created in ChemDraw and BioRender by the Author.



5.1 Animal Studies

Animal models, particularly rodents, have provided valuable insights into the physiological effects of phytoestrogens on insulin sensitivity, glucose metabolism, and related metabolic pathways. These preclinical studies help bridge the gap between molecular mechanisms and clinical applications [55].

5.1.1. Rodent Models and Phytoestrogen-Enriched Diets

Numerous research has examined the effects of phytoestrogens, particularly isoflavones such as genistein and daidzein, as well as lignans like secoisolariciresinol diglucoside (SDG), on metabolic parameters in murine models [56]. Diets supplemented with soy or flaxseed products have demonstrated beneficial metabolic effects:

- Enhanced Glucose Tolerance: Rodents administered phytoestrogens had markedly enhanced oral glucose tolerance and reduced fasting glucose levels relative to control subjects [57].
- Insulin Sensitivity: Rodents consuming phytoestrogen-rich diets exhibited reduced Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) values and enhanced insulin-mediated glucose absorption [58].
- Decrease in Visceral Adiposity: The bulk of adipose tissue, especially visceral fat, was markedly reduced in treated rats, correlating with improved insulin sensitivity.
- Anti-Inflammatory Effects: Diminished expression of inflammatory markers (e.g., TNF-α, IL-6) in adipose and hepatic tissues, enhancing insulin efficacy [59].
- AMPK and GLUT4 Activation: Augmented expression of AMP-activated protein kinase (AMPK) and glucose transporter 4 (GLUT4) in skeletal muscle and liver, facilitating enhanced glucose consumption.

5.1.2 Species Differences and Translational Challenges

While rodent studies have consistently demonstrated metabolic benefits of phytoestrogens, certain limitations should be acknowledged:

- Metabolism Variations**:** Rodents metabolize phytoestrogens differently from humans, especially regarding the formation of active metabolites like equals.
- Gut Microbiota Influence**:** The composition of gut microbiota which significantly affects phytoestrogen metabolism, varies greatly between animal models and humans.
- Dosage Discrepancies**:** Experimental doses used in animal studies often exceed typical human dietary intake, complicating direct clinical translation.

Nonetheless, these studies offer foundational support for the potential of phytoestrogens in managing insulin resistance and related metabolic disorders [60-61].

5.2 Comparison with Traditional Estrogen Therapies

Hormone Replacement Therapy (HRT) has long been used to treat estrogen deficiency in postmenopausal women, with known effects on metabolic regulation. Comparisons between phytoestrogens and traditional estrogen therapies highlight both similarities and critical distinctions [62] .Table 6.2 and illustrated in Figure 6.4.

5.2.1 Metabolic Benefits of HRT

Conventional estrogen therapy has demonstrated improvements in [63-64] :

- Insulin Sensitivity**:** Reduced fasting insulin levels and improved glucose disposal rates.
- Lipid Metabolism**:** Decreased total and LDL cholesterol levels; increased HDL cholesterol.
- Fat Redistribution**:** Reduced central adiposity and improved fat distribution patterns.
- However, the use of HRT is often limited by associated risks:
- Increased Cancer Risk**:** Prolonged use of synthetic estrogens may elevate the risk of hormone-sensitive cancers such as breast and endometrial cancer.
- Cardiovascular Events**:** Depending on timing and patient profile, there is potential for increased risk of thrombosis and cardiovascular disease.

5.2.2 Phytoestrogens: A Natural Alternative

Phytoestrogens, due to their structural similarity to estradiol, exert mild estrogenic effects through selective activation of estrogen receptors predominantly ERβ without the full potency of synthetic estrogens[65] .

Advantages over HRT include:

- Lower Estrogenic Potency**:** Reduced risk of overstimulation of estrogen-sensitive tissues.
- Selective Modulation**:** Preferential binding to ERβ over ERα may provide beneficial metabolic effects with reduced adverse outcomes.
- Fewer Side Effects**:** Phytoestrogens are generally well tolerated and pose lower risk of hormone-related malignancies[67-68].

5.2.3 Clinical Comparisons and Considerations

Clinical trials comparing phytoestrogens with HRT report that while phytoestrogens may not match the potency of traditional estrogen therapy, they still provide:

- Moderate improvements in glycemic control.
- Reduced menopausal symptoms.
- Better lipid profile and anti-inflammatory effects.

Thus, for patients with contraindications to HRT or those seeking a more natural approach, phytoestrogens offer a viable and safer alternative for managing insulin resistance and metabolic dysfunction[69-70].

TABLE 2: Mechanisms of action of phytoestrogens in improving insulin sensitivity.

Parameter	Phytoestrogens	Estrogen Therapy (HRT)	Reference
Source	Plant-based (e.g., soy, flaxseed)	Synthetic or bioidentical estrogens	71
Estrogenic Potency	Weak	Strong	72
Receptor Affinity	ERβ > ERα	ERα ≈ ERβ	73
Insulin Sensitivity	Improves moderately	Improves significantly	74
Lipid Profile	Improves	Improves markedly	75
Cancer Risk	Low	Moderate to high (with prolonged use)	76
Cardiovascular Risk	Low to neutral	Variable (age and timing dependent)	77
Ideal Population	Mild insulin resistance, post menopause	Severe deficiency, menopausal symptoms	78
Tolerability	High	Moderate	79

6. Conclusion

Phytoestrogens, especially isoflavones and lignans, are a promising category of naturally occurring chemicals with considerable potential to improve insulin sensitivity and general metabolic health. These phytochemicals operate via estrogen-dependent and estrogen-independent pathways, encompassing the modulation of estrogen receptors (ERα and ERβ), activation of AMP-activated protein kinase (AMPK), augmentation of GLUT4 expression, and direct influences on pancreatic β-cell functionality and adipocyte metabolism. Randomized clinical trials demonstrate the effectiveness of phytoestrogens, particularly soy isoflavones and flaxseed lignans, in enhancing glycemic control, diminishing insulin resistance, and decreasing HbA1c, fasting glucose, and lipid levels. The advantages are particularly evident in postmenopausal women, a demographic at heightened risk for insulin resistance owing to diminishing estrogen levels. Epidemiological studies corroborate these findings, indicating that increased dietary phytoestrogen consumption is associated with a lower prevalence of type 2 diabetes and improved metabolic profiles. Comparative investigations with conventional estrogen treatments indicate that phytoestrogens may provide analogous advantages without the concomitant hazards of hormone replacement therapy (HRT), including heightened susceptibility to hormone-sensitive malignancies and cardiovascular issues. Furthermore, research utilizing animal models consistently reveal the advantageous metabolic benefits of phytoestrogens, such as enhanced insulin sensitivity, decreased adiposity, and lowered inflammatory markers.

7. Limitations and Future Directions

Despite the encouraging findings, several limitations in the current body of evidence must be acknowledged. One issue is the inconsistent individual response to phytoestrogens**,** largely influenced by whether a person is an equals producers trait dependent on gut microbiota composition. Since equals has higher estrogenic activity than its precursor daidzein, this interindividual variability significantly impacts the therapeutic efficacy of isoflavones [80-81] .

Another concern is the limited availability of long-term safety data**.** While short- and mid-term studies have shown favorable safety profiles, robust data on chronic phytoestrogen use, particularly at high supplemental doses, are lacking. This is especially important when considering use in populations such as postmenopausal women or individuals with estrogen-sensitive conditions [82-83] . Additionally, there are bioavailability challenges associated with phytoestrogen forms. Many isoflavones exist in glycoside forms in foods, which require enzymatic or microbial hydrolysis into aglycones to become bioactive. The efficiency of this conversion varies greatly among individuals and may limit systemic availability [84-85] .

To address these gaps, future research should emphasize:

- Personalized phytoestrogen therapy**,** potentially guided by gut microbiota profiles or genetic markers.
- Development of formulations with enhanced bioavailability**,** such as nanoencapsulation or aglycone-rich extracts.
- Investigations into microbiota-targeted modulation strategies to increase equol production and improve phytoestrogen metabolism.
- Longitudinal studies examining long-term safety**,** efficacy, and endocrine outcomes across diverse populations [86.]

References

1. Petrine, J. C. P.; Del Bianco-Borges, B. The Influence of Phytoestrogens on Different Physiological and Pathological Processes: An Overview. *Phytotherapy Research* 2021, *35* (1), 180–197. https://doi.org/10.1002/PTR.6816.

2. Villa, P.; Costantini, B.; Suriano, R.; Perri, C.; Macrì, F.; Ricciardi, L.; Panunzi, S.; Lanzone, A. The Differential Effect of the Phytoestrogen Genistein on Cardiovascular Risk Factors in Postmenopausal Women: Relationship with the Metabolic Status. *J Clin Endocrinol Metab* 2009, *94* (2), 552–558. https://doi.org/10.1210/JC.2008-0735.
3. Cederroth, C. R.; Vinciguerra, M.; Gjinovci, A.; Kühne, F.; Klein, M.; Cederroth, M.; Caille, D.; Suter, M.; Neumann, D.; James, R. W.; Doerge, D. R.; Wallimann, T.; Meda, P.; Foti, M.; Rohner-Jeanrenaud, F.; Vassalli, J. D.; Nef, S. Dietary Phytoestrogens Activate AMP-Activated Protein Kinase With Improvement in Lipid and Glucose Metabolism. *Diabetes* 2008, *57* (5), 1176–1185. https://doi.org/10.2337/DB07-0630.
4. HERBS AND SPICES - NEW PERSPECTIVES IN HUMAN HEALTH AND FOOD INDUSTRY. 2024.
5. Lee, C. C.; Bloem, C. J.; Kasa-Vubu, J. Z.; Liang, L. J. Effect of Oral Phytoestrogen on Androgenicity and Insulin Sensitivity in Postmenopausal Women. *Diabetes Obes Metab* 2012, *14* (4), 315–319. https://doi.org/10.1111/J.1463-1326.2011.01532.X;WGROUP:STRING:PUBLICATION.
6. Jungbauer, A.; Medjakovic, S. Phytoestrogens and the Metabolic Syndrome. *J Steroid Biochem Mol Biol* 2014, *139*, 277–289. https://doi.org/10.1016/J.JSBMB.2012.12.009.
7. Kwon, D. Y.; Daily, J. W.; Kim, H. J.; Park, S. Antidiabetic Effects of Fermented Soybean Products on Type 2 Diabetes. *Nutrition Research* 2010, *30* (1), 1–13. https://doi.org/10.1016/J.NUTRES.2009.11.004.
8. Van Der Schouw, Y. T.; Pijpe, A.; Lebrun, C. E. I.; Bots, M. L.; Peeters, P. H. M.; Van Staveren, W. A.; Lamberts, S. W. J.; Grobbee, D. E. Higher Usual Dietary Intake of Phytoestrogens Is Associated with Lower Aortic Stiffness in Postmenopausal Women. *Arterioscler Thromb Vasc Biol* 2002, *22* (8), 1316–1322. https://doi.org/10.1161/01.atv.0000027176.83618.1a.
9. Talaei, M.; Pan, A. Role of Phytoestrogens in Prevention and Management of Type 2 Diabetes. *World J Diabetes* 2015, *6* (2), 271. https://doi.org/10.4239/WJD.V6.I2.271.
10. Ingram, D.; Sanders, K.; Kolybaba, M.; Lopez, D. Case-Control Study of Phyto-Oestrogens and Breast Cancer. *Lancet* 1997, *350* (9083), 990–994. https://doi.org/10.1016/s0140-6736(97)01339-1.
11. Rossouw, J. E.; Anderson, G. L.; Prentice, R. L.; LaCroix, A. Z.; Kooperberg, C.; Stefanick, M. L.; Jackson, R. D.; Beresford, S. A. A.; Howard, B. V.; Johnson, K. C.; Kotchen, J. M.; Ockene, J. Risk and Benefits of Estrogen plus Progestin in Healthy Postmenopausal Women. *JAMA* 2002, *288* (3), 321–333. https://doi.org/10.1001/jama.288.3.321.
12. Sites, C. K.; Toth, M. J.; Cushman, M.; L'Hommedieu, G. D.; Tchernof, A.; Tracy, R. P.; Poehlman, E. T. Menopause-Related Differences in Inflammation Markers and Their Relationship to Body Fat Distribution and Insulin-Stimulated Glucose Disposal. *Fertil Steril* 2002, *77* (1), 128–135. https://doi.org/10.1016/s0015-0282(01)02934-x.
13. Carr, M. C. The Emergence of the Metabolic Syndrome with Menopause. *J Clin Endocrinol Metab* 2003, *88* (6), 2404–2411. https://doi.org/10.1210/jc.2003-030242.
14. Pfeilschifter, J.; Köditz, R.; Pfohl, M.; Schatz, H. Changes in Proinflammatory Cytokine Activity after Menopause. *Endocr Rev* 2002, *23* (1), 90–119. https://doi.org/10.1210/edrv.23.1.0456.

15. DeFronzo, R. A.; Ferrannini, E. Insulin Resistance. A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease. *Diabetes Care* 1991, *14* (3), 173–194. https://doi.org/10.2337/diacare.14.3.173.

16. Prasannarong, M.; Saengsirisuwan, V.; Piyachaturawat, P.; Suksamrarn, A. Improvements of Insulin Resistance in Ovariectomized Rats by a Novel Phytoestrogen from Curcuma Comosa Roxb. *BMC Complementary and Alternative Medicine 2012 12:1* 2012, *12* (1), 1–11. https://doi.org/10.1186/1472-6882-12-28.

17. Zamora-Ros, R.; Knaze, V.; Luján-Barroso, L.; Kuhnle, G. G. C.; Mulligan, A. A.; Touillaud, M.; Slimani, N.; Romieu, I.; Powell, N.; Tumino, R.; Peeters, P. H. M.; De Magistris, M. S.; Ricceri, F.; Sonestedt, E.; Drake, I.; Hjartker, A.; Skie, G.; Mouw, T.; Wark, P. A.; Romaguera, D.; Bueno-De-Mesquita, H. B.; Ros, M.; Molina, E.; Sieri, S.; Quirós, J. R.; Huerta, J. M.; Tjønneland, A.; Halkjær, J.; Masala, G.; Teucher, B.; Kaas, R.; Travis, R. C.; Dilis, V.; Benetou, V.; Trichopoulou, A.; Amiano, P.; Ardanaz, E.; Boeing, H.; Förster, J.; Clavel-Chapelon, F.; Fagherazzi, G.; Perquier, F.; Johansson, G.; Johansson, I.; Cassidy, A.; Overvad, K.; González, C. A. Dietary Intakes and Food Sources of Phytoestrogens in the European Prospective Investigation into Cancer and Nutrition (EPIC) 24-Hour Dietary Recall Cohort. *Eur J Clin Nutr* 2012, *66* (8), 932–941. https://doi.org/10.1038/EJCN.2012.36.

18. Viggiani, M. T.; Polimeno, L.; Di Leo, A.; Barone, M. Phytoestrogens: Dietary Intake, Bioavailability, and Protective Mechanisms against Colorectal Neoproliferative Lesions. *Nutrients* 2019, *11* (8). https://doi.org/10.3390/NU11081709.

19. Bennetau-Pelissero, C. Risks and Benefits of Phytoestrogens: Where Are We Now. *Curr Opin Clin Nutr Metab Care* 2016, *19* (6), 477–483. https://doi.org/10.1097/MCO.0000000000000326.

20. Domínguez-López, I.; Yago-Aragón, M.; Salas-Huetos, A.; Tresserra-Rimbau, A.; Hurtado-Barroso, S. Effects of Dietary Phytoestrogens on Hormones throughout a Human Lifespan: A Review. *Nutrients 2020, Vol. 12, Page 2456* 2020, *12* (8), 2456. https://doi.org/10.3390/NU12082456.

21. Wang, S.; Hu, Y.; Liu, B.; Li, Y.; Wang, M.; Sun, Q. Lignan Intake and Type 2 Diabetes Incidence Among US Men and Women. *JAMA Netw Open* 2024, *7* (8), e2426367. https://doi.org/10.1001/JAMANETWORKOPEN.2024.26367.

22. Farkas, S.; Szabó, A.; Hegyi, A. E.; Török, B.; Fazekas, C. L.; Ernszt, D.; Kovács, T.; Zelena, D. Estradiol and Estrogen-like Alternative Therapies in Use: The Importance of the Selective and Non-Classical Actions. *Biomedicines* 2022, *10* (4). https://doi.org/10.3390/BIOMEDICINES10040861.

23. Baudin, J.; Hernandez-Baixauli, J.; Quesada-Vázquez, S.; Mulero, F.; Puiggròs, F.; Arola, L.; Caimari, A. Combined Supplementation with Hesperidin, Phytosterols and Curcumin Decreases Adiposity and Improves Metabolic Health in Ovariectomized Rats. *Food Funct* 2024, *15* (9), 4905–4924. https://doi.org/10.1039/D3FO05122F.

24. Romani, A. M. P. The Controversy on the Beneficial Effect of Phytoestrogens in Diabetic Treatment in Postmenopausal Women. *Biochem Pharmacol* 2021, *190*, 114619. https://doi.org/10.1016/J.BCP.2021.114619.

25. Glisic, M.; Kastrati, N.; Gonzalez-Jaramillo, V.; Bramer, W. M.; Ahmadizar, F.; Chowdhury, R.; Danser, A. H. J.; Roks, A. J. M.; Voortman, T.; Franco, O. H.; Muka, T. Associations between Phytoestrogens, Glucose Homeostasis, and Risk of Diabetes in Women: A Systematic Review and Meta-Analysis. *Advances in Nutrition* 2018, *9* (6), 726–740. https://doi.org/10.1093/ADVANCES/NMY048.

26. Cos, P.; De Bruyne, T.; Apers, S.; Vanden Berghe, D.; Pieters, L.; Vlietinck, A. J. Phytoestrogens: Recent Developments. *Planta Med* 2003, *69* (7), 589–599. https://doi.org/10.1055/S-2003-41122/ID/3/BIB.

27. Bateman, H. L.; Patisaul, H. B. Disrupted Female Reproductive Physiology Following Neonatal Exposure to Phytoestrogens or Estrogen Specific Ligands Is Associated with Decreased GnRH Activation and Kisspeptin Fiber Density in the Hypothalamus. *Neurotoxicology* 2008, *29* (6), 988–997. https://doi.org/10.1016/J.NEURO.2008.06.008.

28. Dixon, R. A. Phytoestrogens. *Annu Rev Plant Biol* 2004, *55* (Volume 55, 2004), 225–261. https://doi.org/10.1146/ANNUREV.ARPLANT.55.031903.141729/CITE/REFWORKS.

29. Delclos, K. B.; Bucci, T. J.; Lomax, L. G.; Latendresse, J. R.; Warbritton, A.; Weis, C. C.; Newbold, R. R. Effects of Dietary Genistein Exposure during Development on Male and Female CD (Sprague-Dawley) Rats. *Reproductive Toxicology* 2001, *15* (6), 647–663. https://doi.org/10.1016/S0890-6238(01)00177-0.

30. Iguchi, T.; Fukazawa, Y.; Uesugi, Y.; Takasugi, N. Polyovular Follicles in Mouse Ovaries Exposed Neonatally to Diethylstilbestrol in Vivo and in Vitro. *Biol Reprod* 1990, *43* (3), 478–484. https://doi.org/10.1095/BIOLREPROD43.3.478.

31. Losa, S. M.; Todd, K. L.; Sullivan, A. W.; Cao, J.; Mickens, J. A.; Patisaul, H. B. Neonatal Exposure to Genistein Adversely Impacts the Ontogeny of Hypothalamic Kisspeptin Signaling Pathways and Ovarian Development in the Peripubertal Female Rat. *Reproductive Toxicology* 2011, *31* (3), 280–289. https://doi.org/10.1016/J.REPROTOX.2010.10.002.

32. Ososki, A. L.; Kennelly, E. J. Phytoestrogens: A Review of the Present State of Research. *Phytotherapy Research* 2003, *17* (8), 845–869. https://doi.org/10.1002/PTR.1364.

33. Brandenberger, A. W.; Tee, M. K.; Lee, J. Y.; Chao, V.; Jaffe, R. B. Tissue Distribution of Estrogen Receptors Alpha (ER-α) and Beta (ER-β) MRNA in the Midgestational Human Fetus. *J Clin Endocrinol Metab* 1997, *82* (10), 3509–3512. https://doi.org/10.1210/JCEM.82.10.4400.

34. Cimafranca, M. A.; Davila, J.; Ekman, G. C.; Andrews, R. N.; Neese, S. L.; Peretz, J.; Woodling, K. A.; Helferich, W. G.; Sarkar, J.; Flaws, J. A.; Schantz, S. L.; Doerge, D. R.; Cooke, P. S. Acute and Chronic Effects of Oral Genistein Administration in Neonatal Mice. *Biol Reprod* 2010, *83* (1), 114–121. https://doi.org/10.1095/BIOLREPROD.109.080549.

35. Jefferson, W. N.; Couse, J. F.; Padilla-Banks, E.; Korach, K. S.; Newbold, R. R. Neonatal Exposure to Genistein Induces Estrogen Receptor (ER)α Expression and Multioocyte Follicles in the Maturing Mouse Ovary: Evidence for ERβ-Mediated and Nonestrogenic Actions. *Biol Reprod* 2002, *67* (4), 1285–1296. https://doi.org/10.1095/BIOLREPROD67.4.1285.

36. Takagi, H.; Shibutani, M.; Lee, K. Y.; Lee, H. C.; Nishihara, M.; Uneyama, C.; Takigami, S.; Mitsumori, K.; Hirose, M. Lack of Modifying Effects of Genistein on Disruption of the Reproductive System by Perinatal Dietary Exposure to Ethinylestradiol in Rats. *Reproductive Toxicology* 2004, *18* (5), 687–700. https://doi.org/10.1016/J.REPROTOX.2004.03.002.

37. Casanova, M.; You, L.; Gaido, K. W.; Archibeque-Engle, S.; Janszen, D. B.; Heck, H. D. A. Developmental Effects of Dietary Phytoestrogens in Sprague-Dawley Rats and Interactions of

Genistein and Daidzein with Rat Estrogen Receptors α and β in Vitro. *Toxicological Sciences* 1999, *51* (2), 236–244. https://doi.org/10.1093/TOXSCI/51.2.236.

38. Lewis, R. W.; Brooks, N.; Milburn, G. M.; Soames, A.; Stone, S.; Hall, M.; Ashby, J. The Effects of the Phytoestrogen Genistein on the Postnatal Development of the Rat. *Toxicological Sciences* 2003, *71* (1), 74–83. https://doi.org/10.1093/TOXSCI/71.1.74.

39. Pepling, M. E.; Spradling, A. C. Mouse Ovarian Germ Cell Cysts Undergo Programmed Breakdown to Form Primordial Follicles. *Dev Biol* 2001, *234* (2), 339–351. https://doi.org/10.1006/DBIO.2001.0269.

40. Hwang, C. S.; Kwak, H. S.; Lim, H. J.; Lee, S. H.; Kang, Y. S.; Choe, T. B.; Hur, H. G.; Han, K. O. Isoflavone Metabolites and Their in Vitro Dual Functions: They Can Act as an Estrogenic Agonist or Antagonist Depending on the Estrogen Concentration. *Journal of Steroid Biochemistry and Molecular Biology* 2006, *101* (4–5), 246–253. https://doi.org/10.1016/J.JSBMB.2006.06.020.

41. Padilla-Banks, E.; Jefferson, W. N.; Newbold, R. R. Neonatal Exposure to the Phytoestrogen Genistein Alters Mammary Gland Growth and Developmental Programming of Hormone Receptor Levels. *Endocrinology* 2006, *147* (10), 4871–4882. https://doi.org/10.1210/EN.2006-0389.

42. Martin, P. M.; Horwitz, K. B.; Ryan, D. S.; McGuire, W. L. Phytoestrogen Interaction with Estrogen Receptors in Human Breast Cancer Cells. *Endocrinology* 1978, *103* (5), 1860–1867. https://doi.org/10.1210/ENDO-103-5-1860.

43. Kuiper, G. G. J. M.; Lemmen, J. G.; Carlsson, B.; Corton, J. C.; Safe, S. H.; Van Der Saag, P. T.; Van Der Burg, B.; Gustafsson, J. Å. Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β. *Endocrinology* 1998, *139* (10), 4252–4263. https://doi.org/10.1210/ENDO.139.10.6216.

44. Couse, J. F.; Lindzey, J.; Grandien, K.; Gustafsson, J. Å.; Korach, K. S. Tissue Distribution and Quantitative Analysis of Estrogen Receptor-α (ERα) and Estrogen Receptor-β (ERβ) Messenger Ribonucleic Acid in the Wild-Type and ERα-Knockout Mouse. *Endocrinology* 1997, *138* (11), 4613–4621. https://doi.org/10.1210/ENDO.138.11.5496.

45. Faber, K. A.; Hughes, C. L. Dose-Response Characteristics of Neonatal Exposure to Genistein on Pituitary Responsiveness to Gonadotropin-Releasing Hormone and Volume of the Sexually Dimorphic Nucleus of the Preoptic Area (SDN-POA) in Postpubertal Castrated Female Rats. *Reproductive Toxicology* 1993, *7* (1), 35–39. https://doi.org/10.1016/0890-6238(93)90007-T.

46. Sarkar, F. H.; Li, Y. Mechanisms of Cancer Chemoprevention by Soy Isoflavone Genistein. *Cancer and Metastasis Reviews* 2002, *21* (3–4), 265–280. https://doi.org/10.1023/A:1021210910821.

47. Enmark, E.; Pelto-Huikko, M.; Grandien, K.; Lagercrantz, S.; Lagercrantz, J.; Fried, G.; Nordenskjöld, M.; Gustafsson, J. Å. Human Estrogen Receptor β-Gene Structure, Chromosomal Localization, and Expression Pattern. *Journal of Clinical Endocrinology and Metabolism* 1997, *82* (12), 4258–4265. https://doi.org/10.1210/JCEM.82.12.4470.

48. Nagao, T.; Yoshimura, S.; Saito, Y.; Nakagomi, M.; Usumi, K.; Ono, H. Reproductive Effects in Male and Female Rats of Neonatal Exposure to Genistein. *Reproductive Toxicology* 2001, *15* (4), 399–411. https://doi.org/10.1016/S0890-6238(01)00141-1.

49. Jefferson, W. N.; Padilla-Banks, E.; Newbold, R. R. Adverse Effects on Female Development and Reproduction in CD-1 Mice Following Neonatal Exposure to the Phytoestrogen Genistein at Environmentally Relevant Doses. *Biol Reprod* 2005, *73* (4), 798–806. https://doi.org/10.1095/BIOLREPROD.105.041277.

50. Setchell, K. D. R. Phytoestrogens: The Biochemistry, Physiology, and Implications for Human Health of Soy Isoflavones. *American Journal of Clinical Nutrition* 1998, *68* (6 SUPPL.). https://doi.org/10.1093/AJCN/68.6.1333S.

51. Takashima-Sasaki, K.; Komiyama, M.; Adachi, T.; Sakurai, K.; Kato, H.; Iguchi, T.; Mori, C. Effect of Exposure to High Isoflavone-Containing Diets on Prenatal and Postnatal Offspring Mice. *Biosci Biotechnol Biochem* 2006, *70* (12), 2874–2882. https://doi.org/10.1271/BBB.60278.

52. Kouki, T.; Kishitake, M.; Okamoto, M.; Oosuka, I.; Takebe, M.; Yamanouchi, K. Effects of Neonatal Treatment with Phytoestrogens, Genistein and Daidzein, on Sex Difference in Female Rat Brain Function: Estrous Cycle and Lordosis. *Horm Behav* 2003, *44* (2), 140–145. https://doi.org/10.1016/S0018-506X(03)00122-3.

53. Kim, S. H.; Park, M. J. Effects of Phytoestrogen on Sexual Development. *Korean J Pediatr* 2012, *55* (8), 265. https://doi.org/10.3345/KJP.2012.55.8.265.

54. Duffy, C.; Perez, K.; Partridge, A. Implications of Phytoestrogen Intake for Breast Cancer. *CA Cancer J Clin* 2007, *57* (5), 260–277. https://doi.org/10.3322/CA.57.5.260;WEBSITE:WEBSITE:ACSJOURNALS.ONLINELIBRARY.WILEY.COM;REQUESTEDJOURNAL:JOURNAL:15424863;WGROUP:STRING:PUBLICATION.

55. Xu, L.; Öjemyr, L. N.; Bergstrand, J.; Brzezinski, P.; Widengren, J. Protonation Dynamics on Lipid Nanodiscs: Influence of the Membrane Surface Area and External Buffers. *Biophys J* 2016, *110* (9), 1993–2003. https://doi.org/10.1016/j.bpj.2016.03.035.

56. Sarao, L.; Kaur, S.; Malik, T.; Singh, A. Genistein and Daidzein. *Nutraceuticals and Health Care* 2021, 331–341. https://doi.org/10.1016/B978-0-323-89779-2.00016-8.

57. Kiyama, R. Biological Effects Induced by Estrogenic Activity of Lignans. *Trends Food Sci Technol* 2016, *54*, 186–196. https://doi.org/10.1016/j.tifs.2016.06.007.

58. Hasler, D.; Lange, M. Renormalization Analysis for Degenerate Ground States. *J Funct Anal* 2018, *275* (1), 103–148. https://doi.org/10.1016/j.jfa.2018.03.005.

59. Glisic, M.; Kastrati, N.; Musa, J.; Milic, J.; Asllanaj, E.; Portilla Fernandez, E.; Nano, J.; Ochoa Rosales, C.; Amiri, M.; Kraja, B.; Bano, A.; Bramer, W. M.; Roks, A. J. M.; Danser, A. H. J.; Franco, O. H.; Muka, T. Phytoestrogen Supplementation and Body Composition in Postmenopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Maturitas* 2018, *115*, 74–83. https://doi.org/10.1016/j.maturitas.2018.06.012.

60. Fry, A. M.; Laugharne, D.; Jones, K. Osteotomising the Fibular Free Flap: An Anatomical Perspective. *British Journal of Oral and Maxillofacial Surgery* 2016, *54* (6), 692–693. https://doi.org/10.1016/j.bjoms.2015.11.009.

61. Enmark, E.; Pelto-Huikko, M.; Grandien, K.; Lagercrantz, S.; Lagercrantz, J.; Fried, G.; Nordenskjöld, M.; Gustafsson, J. Å. Human Estrogen Receptor β-Gene Structure, Chromosomal Localization, and Expression Pattern. *Journal of Clinical Endocrinology and Metabolism* 1997, *82* (12), 4258–4265. https://doi.org/10.1210/JCEM.82.12.4470.

62. Adlercreutz, H.; Mazur, W. Phyto-Oestrogens and Western Diseases. *Ann Med* 1997, *29* (2), 95–120. https://doi.org/10.3109/07853899709113696.

63. Kurzer, M. S.; Xu, X. Dietary Phytoestrogens. *Annu Rev Nutr* 1997, *17*, 353–381. https://doi.org/10.1146/ANNUREV.NUTR.17.1.353.

64. Tham, D. M.; Gardner, C. D.; Haskell, W. L. Potential Health Benefits of Dietary Phytoestrogens: A Review of the Clinical, Epidemiological, and Mechanistic Evidence. *Journal of Clinical Endocrinology and Metabolism* 1998, *83* (7), 2223–2235. https://doi.org/10.1210/JC.83.7.2223.

65. Izumi, T.; Piskula, M. K.; Osawa, S.; Obata, A.; Tobe, K.; Saito, M.; Kataoka, S.; Kubota, Y.; Kikuchi, M. Soy Isoflavone Aglycones Are Absorbed Faster and in Higher Amounts than Their Glucosides in Humans. *Journal of Nutrition* 2000, *130* (7), 1695–1699. https://doi.org/10.1093/jn/130.7.1695.

66. Herman, C.; Adlercreutz, T.; Goldin, B. R.; Gorbach, S. L.; Hockerstedt, K. A. V.; Watanabe, S.; Hamalainen, E. K.; Markkanen, M. H.; Makela, T. H.; Wahala, K. T.; Hase, T. A.; Fotsis, T. Soybean Phytoestrogen Intake and Cancer Risk. *J Nutr* 1995, *125* (3 SUPPL.), 757S-770S. https://doi.org/10.1093/JN/125.3_SUPPL.757S.

67. Kurzer, M. S. Phytoestrogen Supplement Use by Women. *J Nutr* 2003, *133* (6), 1983S-1986S. https://doi.org/10.1093/JN/133.6.1983S.

68. Cassidy, A. Potential Risks and Benefits of Phytoestrogen-Rich Diets. *http://dx.doi.org/10.1024/0300-9831.73.2.120* 2013, *73* (2), 120–126. https://doi.org/10.1024/0300-9831.73.2.120.

69. Stüfchen, I.; Williams, T. A.; Schweizer, J. R. O. L.; Völter, F.; Zopp, S.; Petersenn, E.; Bidlingmaier, M.; Brüdgam, D.; Kroiss, M.; Oettle, M.; Schrenk, M.; Zimmermann, P.; Reincke, M. Persistent Renin Suppression after Unilateral Adrenalectomy for Primary Aldosteronism: Implications for Adverse Outcome? *J Clin Endocrinol Metab* 2025. https://doi.org/10.1210/CLINEM/DGAF595.

70. Kontola, H.; Crisóstomo, L.; Löyttyniemi, E.; Koskenniemi, J. J.; Veijola, R.; Toppari, J.; Kero, J. Altered Glucagon Response to Oral Glucose in Individuals at Different Stages of Type 1 Diabetes Development. *J Clin Endocrinol Metab* 2025. https://doi.org/10.1210/CLINEM/DGAF601.

71. Sharp, L. N.; Colclough, K.; Murray Leech, J.; Cannon, S. J.; Laver, T. W.; Hattersley, A. T.; Weedon, M. N.; Patel, K. A. Population Prevalence, Penetrance, and Mortality for Genetically Confirmed MODY. *J Clin Endocrinol Metab* 2025. https://doi.org/10.1210/CLINEM/DGAF599.

72. Chatterjee, S.; Ishida, M.; Bertola, D. R.; Agwu, J. C.; Gaston-Massuet, C.; McGuffin, L. J.; Storr, H. L.; Maharaj, A. V. Pathogenesis of Noonan Syndrome Is Modulated by NOC2L, a Novel Interactor of LZTR1 Leading to Impaired P53 Signalling. *J Clin Endocrinol Metab* 2025. https://doi.org/10.1210/CLINEM/DGAF602.

73. Murkies, A. L.; Wilcox, G.; Davis, S. R. Phytoestrogens. *J Clin Endocrinol Metab* 1998, *83* (2), 297–303. https://doi.org/10.1210/JCEM.83.2.4577.

74. Reinli, K.; Block, G. Phytoestrogen Content of Foods - A Compendium of Literature Values. *Nutr Cancer* 1996, *26* (2), 123–148. https://doi.org/10.1080/01635589609514470;PAGE:STRING:ARTICLE/CHAPTER.

75. Wuttke, W.; Jarry, H.; Becker, T.; Schultens, A.; Christoffel, V.; Gorkow, C.; Seidlová-Wuttke, D. Phytoestrogens: Endocrine Disrupters or Replacement for Hormone Replacement Therapy? *Maturitas* 2003, *44* (SUPPL.). https://doi.org/10.1016/S0378-5122(02)00344-4.

76. Yanagihara, N.; Zhang, H.; Toyohira, Y.; Takahashi, K.; Ueno, S.; Tsutsui, M.; Takahashi, K. New Insights into the Pharmacological Potential of Plant Flavonoids in the Catecholamine System. *J Pharmacol Sci* 2014, *124* (2), 123–128. https://doi.org/10.1254/jphs.13R17CP.

77. Kim, S. H.; Chen, G.; King, A. N.; Jeon, C. K.; Christensen, P. J.; Zhao, L.; Simpson, R. U.; Thomas, D. G.; Giordano, T. J.; Brenner, D. E.; Hollis, B.; Beer, D. G.; Ramnath, N. Characterization of Vitamin D Receptor (VDR) in Lung Adenocarcinoma. *Lung Cancer* 2012, *77* (2), 265–271. https://doi.org/10.1016/j.lungcan.2012.04.010.

78. Wang, L. Q. Mammalian Phytoestrogens: Enterodiol and Enterolactone. *J Chromatogr B Analyt Technol Biomed Life Sci* 2002, *777* (1–2), 289–309. https://doi.org/10.1016/S1570-0232(02)00281-7.

79. Makarevich, A.; Sirotkin, A.; Taradajnik, T.; Chrenek, P. Effects of Genistein and Lavandustin on Reproductive Processes in Domestic Animals in Vitro. *Journal of Steroid Biochemistry and Molecular Biology* 1997, *63* (4–6), 329–337. https://doi.org/10.1016/S0960-0760(97)00092-7.

80. Jefferson, W. N.; Williams, C. J. Circulating Levels of Genistein in the Neonate, Apart from Dose and Route, Predict Future Adverse Female Reproductive Outcomes. *Reproductive Toxicology* 2011, *31* (3), 272–279. https://doi.org/10.1016/j.reprotox.2010.10.001.

81. Sumien, N.; Chaudhari, K.; Sidhu, A.; Forster, M. J. Does Phytoestrogen Supplementation Affect Cognition Differentially in Males and Females? *Brain Res* 2013, *1514*, 123–127. https://doi.org/10.1016/j.brainres.2013.02.013.

82. Eden, J. A. Phytoestrogens for Menopausal Symptoms: A Review. *Maturitas* 2012, *72* (2), 157–159. https://doi.org/10.1016/j.maturitas.2012.03.006.

83. Low Dog, T. Menopause: A Review of Botanical Dietary Supplements. *American Journal of Medicine* 2005, *118* (12 SUPPL. 2), 98–108. https://doi.org/10.1016/j.amjmed.2005.09.044.

84. Paterni, I.; Granchi, C.; Katzenellenbogen, J. A.; Minutolo, F. Estrogen Receptors Alpha (ERα) and Beta (ERβ): Subtype-Selective Ligands and Clinical Potential. *Steroids* 2014, *90*, 13–29. https://doi.org/10.1016/J.STEROIDS.2014.06.012.

85. Van Die, M. D.; Bone, K. M.; Williams, S. G.; Pirotta, M. V. Soy and Soy Isoflavones in Prostate Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *BJU Int* 2014, *113* (5 B). https://doi.org/10.1111/bju.12435.

86. Böttner, M.; Thelen, P.; Jarry, H. Estrogen Receptor Beta: Tissue Distribution and the Still Largely Enigmatic Physiological Function. *Journal of Steroid Biochemistry and Molecular Biology* 2014, *139*, 245–251. https://doi.org/10.1016/j.jsbmb.2013.03.003.